Pharmacotherapy of mania in Japan

Masahiko Ichiki, M.D., Ph.D.*, Jiro Masuya, M.D., Ph.D.*, Takeshi Inoue, M.D., Ph.D.

Department of Psychiatry, Tokyo Medical University, Tokyo, Japan

ABSTRACT

This review introduces the treatment guidelines of acute mania by the Japanese Society of Mood Disorders (JSMD) and compares it with that of the Canadian Network for Mood and Anxiety Treatments (CANMAT). Lithium alone for mild mania and the combination of lithium and some atypical antipsychotic drugs for more severe mania are recommended by the JSMD guidelines. This recommendation is different from that of the CANMAT. As maintenance treatment after treatment of the acute phase should be considered from the start of treatment and lithium is the most recommended drug for maintenance treatment in the JSMD guideline, lithium becomes the critical drug for the treatment of mania in the JSMD guidelines. The so-called "drug lag" accounts for the difference between the two guidelines. Safer drugs for extrapyramidal symptoms and cognitive function should be preferred, because these adverse effects interfere with the functional recovery of bipolar patients. The adverse effects of hypnotics or alcohol on cognitive function should be noted carefully, because cognitive impairment influences disabilities and quality of life (QOL) in bipolar patients. New understanding of the pathophysiology of bipolar disorder, that is circadian rhythm dysfunction, may lead to its new diagnosis and treatment.

Keywords: Mania, bipolar disorder, pharmacotherapy, lithium

Received February 11, 2020 / Accepted February 11, 2020 / Published March 30, 2020.

Introduction

Pharmacotherapy of bipolar disorder has made dramatic progress since the 2000s. In contrast to manic episodes, pharmacotherapy for depressive episodes and maintenance is underdeveloped. There have been several clinical trials into the manic episodes of bipolar disorder; a network meta-analysis was reported by Cipriani and his colleagues [1]. However, there is a gap in the number of approved drugs among countries. In general, there are fewer approved drugs in Japan than in the USA. On the other hand, some drugs approved for mania in Japan, which are old typical antipsychotic drugs including haloperidol and levomepromazine, are not approved for mania in the USA. The latter gap is not welcome because these old drugs can cause several severe side effects. Thus, this comparison of approved drugs between different countries gives us an important idea. Without possession of overseas information, we cannot ensure that the knowledge of pharmacotherapy is both correct and up-to-date, and any wrong understandings may not be noticed. In this article, we reviewed the pharmacotherapy of mania in Japan in comparison with those in the USA and Canada, along with the clinically important points for the treatment of mania.

*Equally contributed to this paper and will be designated as co-first authors.
The state of approval for mania in Japan and USA

Table 1 shows the drugs approved for mania in Japan and the USA. Mood stabilizers (lithium, valproic acid, and carbamazepine) are approved for mania in both countries. Although two atypical antipsychotic drugs, aripiprazole and olanzapine, are approved in both countries, four other atypical antipsychotic drugs, quetiapine, ziprasidone, asenapine, and risperidone, are approved in the USA but not Japan. On the other hand, older typical antipsychotic drugs, such as haloperidol, are approved in Japan but not the USA. In general, more atypical antipsychotic drugs, which are clearly safer than typical antipsychotic drugs, are used clinically in the USA. This drug lag [2] should be resolved for bipolar patients. Older typical antipsychotic drugs approved for mania in Japan raise another problem by indicating that outdated treatment remains in Japan. Especially, extrapyramidal symptoms caused by typical antipsychotic drugs and cognitive disturbances caused by anticholinergic drugs frequently co-used with typical antipsychotic drugs may worsen the symptoms and quality of life of bipolar patients [3, 4].

How to choose antimanic drugs

Past clinical trials have shown that several drugs have a significant antimanic effect when compared with placebo [1]. It is noteworthy whether there are any clinical differences in efficacy and adverse effects between antimanic drugs, which leads to knowing how to choose antimanic drugs, i.e., compatible medications for each patient. A network meta-analysis study showed that, overall, antipsychotic drugs were more effective than mood stabilizers such as lithium, and that risperidone, olanzapine, and haloperidol were considered among the best of the available options for the treatment of manic episodes [1]. These antipsychotic drugs were superior to other antimanic drugs in both efficacy and acceptability. In their study, acceptability meant treatment discontinuation and was defined as the number of patients who left the study early for any reason during the first 3 weeks of treatment of the total number of patients randomly assigned to each treatment group [1]. Acceptability did not mean lack of adverse effects.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) and the International Society for Bipolar Disorders (ISBD) 2018 guidelines recommend lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine as first-line monotherapies for acute mania [5]. These guidelines recommend quetiapine, asenapine, aripiprazole, and risperidone in combination with lithium or divalproex as first-line combination therapies for acute mania. They do not recommend haloperidol and olanzapine as first-line, which have shown superior efficacy and acceptability in the network meta-analysis by Cipriani et al. [1] because safety and tolerability concerns relegated them to second-line options. Extrapyramidal symptoms induced by haloperidol and weight gain and diabetes mellitus induced by olanzapine are se-
Table 2. Treatment guidelines for manic episodes in the third edition of the Japanese Society of Mood Disorders for treatment of bipolar disorders [6] (https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/180125.pdf)

- **Most recommended treatment**
  - When the manic condition is intermediate or severe:
    - Lithium and atypical antipsychotic drugs (olanzapine, aripiprazole, quetiapine, risperidone) in combination
  - In mild manic conditions:
    - Lithium
- **Next recommended treatment**
  - Valproic acid
  - Atypical antipsychotic drugs (olanzapine, aripiprazole, quetiapine, risperidone, paliperidone, asenapine)
  - Carbamazepine
  - Combination of valproic acid and an atypical antipsychotic drug
- **Other recommended treatment**
  - Combination of two or more mood stabilizers
  - Mood stabilizers and typical antipsychotic drugs (chlorpromazine, sultopride, haloperidol, levomepromazine, timiperone, zotepine) in combination
  - Electroconvulsive therapy
- **Treatments that are not recommended**
  - Lamotrigine
  - Topiramate
  - Verapamil

Trichloroacetic acid that affect their choice.

Therefore, not only evidence from meta-analyses, but also comprehensive clinical judgment is needed for drug selection.

**Treatment guidelines for acute mania in Japan**

The Japanese Society of Mood Disorders (JSMD) established a committee for the treatment of mood disorders that created the first edition of a treatment guideline for bipolar disorders on March 10, 2011 and a revised second edition on March 31, 2012 [6]. In 2017, a third edition was revised and distributed through the home page of the JSMD in Japanese (https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/180125.pdf). The recommendations for acute mania in the third edition (Table 2) are almost same as those in the second edition, which was published in an English journal [6]. This guideline recommends lithium monotherapy in mild manic conditions and lithium in combination with atypical antipsychotic drugs (olanzapine, aripiprazole, quetiapine, and risperidone) when the manic condition is intermediate or severe.

Although the CANMAT/ISBD guidelines recommend lithium, divalproex, or atypical antipsychotic drugs as first-line monotherapies, the Japanese guidelines do not recommend divalproex or atypical antipsychotic drugs as first-line monotherapies. The characteristic points of the Japanese guidelines are that the main drug for acute mania is lithium and that atypical antipsychotic drugs are used as adjuvant drugs to lithium. Such a combination of lithium and atypical antipsychotic drugs is also recommended as first-line combination therapies in the CANMAT/ISBD guidelines [5]. Therefore, the Japanese guidelines for acute mania overlap with the CANMAT/ISBD guidelines and the latter recommends more varied treatment options, especially with regards to monotherapies with atypical antipsychotic drugs.

The reason for the recommendation of monotherapy with atypical antipsychotic drugs for acute mania is associated with subsequent recommendations for maintenance treatment. As shown in Table 3, the Japanese guidelines recommends lithium as the most recommended treatment for maintenance. The CANMAT/ISBD guidelines recommend lithium, lamotrigine, divalproex, and atypical antipsychotic drugs as first-line treatments for maintenance. Following the treatment of acute mania, maintenance treatment should be started in all bipolar patients, because bipolar episodes recur frequently without maintenance treatment. Treatment options for maintenance may influence the treatment options for the acute mania.
Table 3. Treatment guidelines for maintenance treatment in the third edition of the Japanese Society of Mood Disorders for the treatment of bipolar disorders [6] (https://www.secretariat.ne.jp/jsmd/inkai/katsudou/data/180125.pdf)

A. Drug therapy
- Most recommended treatment
  Lithium
- Next recommended treatment
  Lamotrigine
  Valproic acid
  Atypical antipsychotic drugs (olanzapine, aripiprazole, quetiapine, paliperidone)
  Combination of lithium and lamotrigine
  Combination of lithium and valproic acid
  Combination of lithium/valproic acid and quetiapine
  Combination of lithium and aripiprazole

- Other recommended treatment
  Carbamazepine
  Risperidone depot injection
  Combination among mood stabilizers or a combination of mood stabilizers and atypical anti-psychotic drugs
  Combination of lithium and thyroid hormones
  Addition of ramelteon to the above recommended drugs

- Treatments that are not recommended
  Use of antidepressants (in particular, tricyclic antidepressants)
  Treatment with antidepressants alone

B. Psychosocial treatment (Combination with drug therapy in all cases)
- Most recommended treatment
  Psychoeducation
- Next recommended treatment
  Cognitive behavioral therapy
  Interpersonal-social rhythm therapy
  Family therapy

- Treatments that are not recommended
  Treatment with psychosocial treatment alone without drug therapy

In our opinion, maintenance treatment should be started alongside the acute mania treatment to prevent a switch to depression following acute mania, rapid cycling, or mixed state [7]. The third edition of the JSMD guidelines for treatment of bipolar disorders recommend psychosocial treatment in combination with pharmacological treatment for maintenance treatment; the most recommended psychosocial treatment of bipolar disorder is psychoeducation. First, patients should have psychoeducation for manic or hypomanic states as well as a mixed state, because these states of bipolar disorder are difficult for patients and their families to understand. The authors used the Manic Episode Screening Questionnaire (MES) to explain the symptoms that constitute manic or hypomanic syndromes (states) to the patients and their families [8]. Understanding the clinical concepts of (hypo) manic states and mixed states may lead to enough insight into bipolar disorder and therefore, good adherence to long-term maintenance treatment.

Cognitive impairment in bipolar disorder

A recent clinical topic in psychiatry is cognitive impairment in endogenous psychiatric diseases, including bipolar disorder. Executive function and processing are the cognitive domains affected in euthymic bipolar outpatients, and such deficits are maintained over time for at least 2 years [9]. In euthymic bipolar patients, both subjective and objective cognitive function predict quality of life [10], even after controlling for the influence of mood symptoms [11]. The International Society for Bipolar Disorders Targeting Cognition Task Force recommends the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) as a screening tool for subjective cognitive impairment, in addition to an objective cognitive assessment in a clinical context [12]. Clinically, a self-reported
questionnaire is more convenient for the screening of cognitive impairment and evaluation of its improvement or worsening.

Recently, attention has focused on the effects of drugs for bipolar disorder on cognitive function [13]. There is some evidence that while lithium improves some cognitive domains, it impedes others. Antipsychotics may be deleterious to cognition, although this may relate to the patient population in which they were prescribed. Sodium valproate is also associated with worse cognitive outcomes, while the impact of other antiepileptics is unclear. Overall the quality of evidence is poor and is derived from a relatively small number of studies that often do not account for the significant heterogeneity of the disorder or common comorbidities.

At this time, it seems that anticholinergics and benzodiazepine anxiolytics or hypnotics should be avoided as much as possible in the treatment of bipolar disorder because these classes of drug impair cognitive function [3, 14, 15]. These drugs are expected to adversely affect the cognitive function of bipolar disorder and thus quality of life (QOL). Treating cognitive impairment in bipolar disorder is an attractive idea. However, it is more important to eliminate factors such as drugs and alcohol that cause cognitive impairment before that.

Circadian rhythm sleep-wake disorders

Another topic in the diagnosis and treatment of bipolar disorder is comorbidity of the circadian rhythm sleep-wake disorders. Irregularity of the sleep-wake rhythm, eveningness chronotype, abnormality of melatonin secretion, vulnerability of clock genes, and the irregularity of social time cues have also been well-documented in bipolar disorder [16]. Circadian rhythm dysfunction is more prominent in BD when compared with that in major depressive disorders and acts as a predictor for the early onset age of BD and the relapse of mood episodes [16]. Hence, treating circadian rhythm dysfunction in bipolar disorder is a new therapeutic target. Melatonin and agonists of melatonin receptors, light therapy and dark therapy, and interpersonal social rhythm therapy, which is recommended as psychosocial maintenance treatment by the JSMD bipolar disorder treatment guidelines, hold promise for the treatment of circadian rhythm dysfunction.

For the treatment of acute mania, adjunctive darkness therapy is reportedly effective. Furthermore, the use of blue - blocking glasses, a kind of sunglass, is also effective in acute mania [17].

Conclusion

The present review introduced the treatment guidelines for bipolar mania by the JSMD and approved drugs in Japan and compared those with those of the CANMAT and approved drugs in the USA. The so-called ‘drug lag’ accounts for the difference in the guidelines and treatment statuses of bipolar disorder between countries. Safer drugs are preferred in modern psychiatric treatment. More recently, the adverse effect of antimanic drugs, hypnotics, or alcohol should be noted carefully because cognitive impairment influences disabilities and QOL in bipolar patients. New understanding of the pathophysiology of bipolar disorder, that is circadian rhythm dysfunction, may lead to its new diagnosis and treatment.

CONFLICT OF INTEREST

Takeshi Inoue has received personal fees from Pfizer, Takeda Pharmaceutical, Kyowa Pharmaceutical Industry, MSD, and Dainippon Sumitomo Pharma. The authors report no other conflicts of interest in this work.

REFERENCES

[1] Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378: 1306-1315.
[2] Wardell WM. Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther 1973; 14: 773-790.
[3] Ogino S, Miyamoto S, Tenjin T, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 78-83.
[4] Sadock B, Sadock V, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, Eleventh Edition. Philadelphia: Lippincott Williams & Wilkins, Inc., 2014.
[5] Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Soci-
Pharmacotherapy of mania in Japan

[4] ety for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97-170.

[6] Kanba S, Kato T, Terao T, Yamada K, Committee for Treatment Guidelines of Mood Disorders JSMD. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci 2013; 67: 285-300.

[7] Takeshima M. Early recognition and appropriate pharmacotherapy for mixed depression: the key to resolving complex or treatment-refractory clinical cases. Clin Neuropsychopharmacol Ther 2019; 10: 10-17.

[8] Kameyama R, Inoue T, Uchida M, et al. Development and validation of a screening questionnaire for present or past (hypo)manic episodes based on DSM-IV-TR criteria. J Affect Disord 2013; 150: 546-550.

[9] Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry 2008; 69: 712-719.

[10] Toyoshima K, Kako Y, Toyomaki A, et al. Associations between cognitive impairment and quality of life in euthymic bipolar patients. Psychiatry Res 2019; 271: 510-515.

[11] Xiao L, Gao Y, Zhang L, Chen P, Sun X. The relationship between cognitive function and quality of life in euthymic Chinese patients with bipolar disorder. Psychiatry Res 2016; 246: 427-431.

[12] Miskowiak KW, Burdick KE, Martinez-Aran A, et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar Disord 2018; 20: 184-194.

[13] Xu N, Huggon B, Saunders KEA. Cognitive impairment in patients with bipolar disorder: impact of pharmacological treatment. CNS Drugs 2020; 34: 29-46.

[14] Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37-48.

[15] Kitajima R, Miyamoto S, Tenjin T, et al. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 300-306.

[16] Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci 2018; 72: 673-682.

[17] Shirahama M, Terao T, Hatano K, Hirakawa H, Ishii N. Use of gray sunglasses to alleviate hypomanic state in two patients with bipolar II disorder. Bipolar Disord 2019; 21: 182-184.